# Semaglutide weight loss over time

> Weight over time | GLP-1 Life Coach — The weight-over-time card at GLP-1 Life Coach: the STEP 1 weight result, longer follow-up in STEP 5, and why duration deserves attention.

**The weight card**

The size of a change and the time it lasts are separate reasons to pay attention. I want both on the table.

## The STEP 1 result

STEP 1 enrolled adults with overweight or obesity without diabetes. In this randomized trial, the [mean body-weight change at 68 weeks was −14.9% with semaglutide and −2.4% with placebo](https://pubmed.ncbi.nlm.nih.gov/33567185/). The semaglutide group received a study dose of 2.4 mg.

That comparison is the useful starting point. Both figures describe a change from baseline, the starting body weight. They describe group averages, so treating either as a personal destination adds a certainty the finding cannot supply. I’d give the comparison a prominent card and leave room around it for the rest of the story.

The diagram puts the reported endpoints on the same scale. I trust this spare comparison more than a smooth curve that fills the intervening weeks with guesses.

![Two bars compare mean weight change at 68 weeks: semaglutide −14.9% and placebo −2.4%.](images/step-1-weight-change.svg)

*Mean change from starting body weight in adults with overweight or obesity without diabetes in [STEP 1](https://pubmed.ncbi.nlm.nih.gov/33567185/).*

## 104 weeks in STEP 5

STEP 5 examined a longer stretch of treatment. In adults with overweight or obesity, semaglutide produced [sustained, clinically meaningful weight loss over 104 weeks, significantly greater than placebo](https://pubmed.ncbi.nlm.nih.gov/36216945/).

I like the patience of that question. A large change makes a good headline; a change still present much later has a different practical meaning. The longer trial earns attention even without borrowing a dramatic percentage from the earlier study.

These are separate trials. Lining their findings up helps frame the question of duration, while joining them into one continuous curve would create a trajectory that neither study reported. That temptation seems particularly strong when a result is turned into a story about a person’s future. I’ll take the less tidy account: a substantial result in STEP 1, followed by evidence of sustained benefit in STEP 5.

## Following the calendar

The longer [STEP 5 result](https://pubmed.ncbi.nlm.nih.gov/36216945/) concerns treatment with semaglutide. The conditions surrounding a durable change deserve as much curiosity as the change itself, especially when I try to picture ordinary life around it. That curiosity is a reason to ask for more information, rather than to invent a successful maintenance routine.

I object to progress reports that turn every change on a scale into a verdict on someone’s effort. The research question here is about treatment and outcomes. A moral score adds nothing useful to it. Equally, an encouraging long-term result cannot tell an individual how treatment will feel or which outcome will matter most to them.

That is where this card hands the conversation on. The [side-effects card](/side-effects) concerns tolerability, and the [health-outcomes card](/health-outcomes) follows results that a scale cannot record. I’d rather have those pages open together than let the weight figure make every decision in the room.

---

GLP-1 Life Coach is my notebook on semaglutide’s published research and everyday follow-through, with no coaching business here and no medical advice in its pages.